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See Article, pages 1038–1045Primary biliary cirrhosis [1] (PBC) is an enigmatic liver
disease of predominantly middle-aged women that may
slowly progress to cirrhosis and liver failure. Patients
are often asymptomatic at the time of diagnosis, but
may present with disabling fatigue, recurrent pruritus
and progressive jaundice. A diagnosis of PBC is made
‘‘with conﬁdence” [2] when biochemicalmarkers of chole-
stasis (alkaline phosphatase, c-glutamyltransferase) are
elevated in the presence of serumAMA (P1:40); compat-
ible histological ﬁndings conﬁrm the diagnosis and allow
staging before therapeutic intervention.
Unravelling the pathogenesis of PBC remains one of
the major challenges in hepatology. PBC is regarded as a
model autoimmune disease which develops from inter-
action between environmental factors and inherited
genetic predisposition [3]. A concordance rate of about
60% for monozygotic twins (as opposed to 0% for dizy-
gotic twins) [4] and familial clustering in 1–6% in com-
parison to a prevalence of 0.02–0.04% in the general
population in northern Europe and the U.S. [5,6] mirror
the impact of genetic factors on development of PBC. It
remains still open to speculation whether the female
preponderance (gender ratio 9:1) reﬂects a potential X
chromosome-linked major locus of susceptibility: genes
involved in immune responsiveness or sex hormone
homeostasis are located on the X chromosome. There
could also be a protective role of Y-linked genes,0168-8278/$34.00  2008 European Association for the Study of the Liver.
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enhanced X monosomy in PBC [7], or just a gender-spe-
ciﬁc exposure to environmental triggers like cosmetics
[8] or nail polishers [9].
Genetic linkage studies in aﬀected families as well as
association studies in large cohorts of unrelated patients
may disclose genetic variants conferring susceptibility or
inﬂuencing progression and severity of a disease. In
PBC, no linkage studies in aﬀected families are avail-
able. Association studies in the past targeted candidate
genes encoding immune modulatory proteins and genes
encoding proteins involved in bile formation. The results
were disappointing. Gene loci reported to be associated
with PBC showed either a weak association or were not
replicated [4].
In the present issue of this Journal, Poupon et al. [10]
made a new eﬀort to gain further insight into contribut-
ing genetic factors in the development and progression
of PBC. Several aspects of this work make it unconven-
tional and a stimulus to further investigations.
The authors selected 15 candidate genes: two related to
immunity encoding cytotoxic T lymphocyte antigen 4
(CTLA-4) and tumor necrosis factor a (TNFa); ten
related to bile formation encoding hepatobiliary trans-
porters; and three related to adaptive response to chole-
stasis encoding nuclear receptors. They included a
cohort of 258PBCpatients in comparison to two indepen-
dent control groups of 286 and 269 healthy volunteers,
respectively. By sequencing all exons, ﬂanking intron
sequences and the 50 and30 untranslated regions in 32 indi-
viduals, they identiﬁed 42 haplotype-tagging single nucle-
otide polymorphisms (htSNPs), of which 12 were novel at
the time of detection. The screening strategy allowed the
detection of htSNPs of >5% frequency covering 96% of
the genetic variance.Published by Elsevier B.V. All rights reserved.
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and TNFa showed diﬀerences in distribution between
PBC and controls suggesting a potential role of CTLA-
4 and TNFa variants in the pathogenesis of PBC. In
contrast, htSNPs of the 12 transporter genes as well as
the 3 nuclear receptor genes under study were equally dis-
tributed. These ﬁndings were not unexpected as CTLA-4
[11] and TNFa polymorphisms [12] aﬀect various
immune-mediated disorders whereas htSNPs of selected
transporters had been studied in the past without major
impact [13,14].
In a second approach, Poupon et al. [10] tested a
potential association of the identiﬁed gene polymor-
phisms with disease severity at the time of diagnosis.
Although the association of htSNPs in the multidrug
resistance 1 gene, ABCB1/MDR1, and the pregnane X
receptor gene, NR1L2/PXR, with more severe disease
did not hold after stringent correction for multiple test-
ing, this may provide an interesting lead for replicative
studies in the future.
The somewhat hidden jewel in this work is conﬁned in
the progression proﬁles of a subgroup of 147 patients with
PBC treated with ursodeoxycholic acid (UDCA). Pro-
gression was deﬁned as hyperbilirubinemia (>2 mg/dl),
evolution towards cirrhosis, and referral to liver trans-
plantation. A Cox regression analysis revealed serum bil-
irubin, alkaline phosphatase, albumin, and the SLC4A2/
AE2 variant rs2303932 as potential independent prognos-
tic factors for disease progression in PBC patients. While
the former three factors have been documented as surro-
gate markers of prognosis in PBC in the past, the ﬁnding
of anAE2 variant as a strong and independent prognostic
factor for disease progression in PBC under UDCA ther-
apy deserves particular attention.
This ﬁnding suggests that cholangiocyte dysfunction
may contribute to or aggravate the immune response
against these cells. Thus, if cholangiocytes undergo
apoptosis at higher than normal rates, this might lead
to enhanced presentation of antigenic epitopes like pyru-
vate dehydrogenase complex-E2 (PDC-E2: the mito-
chondrial antigenic polypeptide structure against
which T cell responses as well as AMA are directed in
PBC) and/or accelerated destruction of bile ducts. Con-
sequently, genetic variants that give rise to reduced cho-
langiocyte function may accelerate disease progression.
The AE2 gene encodes a chloride/bicarbonate
exchanger that is involved in intracellular pH homeosta-
sis and cell volume regulation [15]. AE2 gives rise to sev-
eral isoforms of the transporter by alternative
transcription and is ubiquitously expressed in tissues
of the body. In most epithelia it is present in the basolat-
eral membrane, but, strikingly, in hepatocytes and cho-
langiocytes it was reported to be present in the apical
membrane, which raises the possibility that it is involved
in bicarbonate excretion into bile. Prieto, Medina and
coworkers reported a decade ago that AE2 expression[16] as well as biliary bicarbonate secretion [17] are
impaired in PBC. This does not appear to be a genetic
defect as UDCA treatment led to a partial recovery of
AE2 expression [16] and biliary bicarbonate secretion
[17]. However, secondary reduction in AE2 expression
(e.g. due to local inﬂammation) might accelerate cholan-
giocyte dysfunction with consequently a faster destruc-
tion of bile ducts in PBC. It could be assumed that
genetic variants that are associated with decreased
AE2 function have similar detrimental eﬀects under
pathological conditions. It is important to note, that
knockout mice with a disruption of most isoforms of
Ae2 develop symptoms of PBC [18]. Strikingly, the var-
iant haplotype of AE2 reported in the study by Poupon
et al. [10] negatively correlated with PBC disease pro-
gression suggesting that this haplotype may improve
rather than impair cholangiocyte function.
Alternatively, this AE2 variant could inﬂuence the
antigenic response by an altered lymphocyte pH homeo-
stasis which would inﬂuence T-cell balance. Indeed,
Salas et al. observed a decreased number of T regulatory
cells (Tregs) in mice with a disrupted Ae2 gene [18]. We
have recently shown that the absence of Ae2 in ﬁbro-
blasts [19] and lymphocytes [18] leads to a sustained
increase in intracellular pH. Interestingly, this cytosolic
alkalinization induces higher cAMP levels in ﬁbroblasts
[19], a phenomenon that is most likely driven by bicar-
bonate-stimulated soluble adenylate cyclase [20]. Con-
comitantly, these ‘‘alkalinized cells” with increased
cAMP levels have a sustained induction of inducible
cAMP early repressor (ICER). ICER is the only mem-
ber of the cAMP response element binding and modula-
tor (CREB/CREM) family of transcription factors that
acts as a direct repressor. ICER may play a crucial role
in peripheral conversion of responder T cells into Tregs
by inhibition of TGF-b mediated induction of Foxp3
expression [21]. Hence, disturbance of intracellular pH
homeostasis may have important consequences for T
cell diﬀerentiation. It remains to be demonstrated
whether soluble adenylate cyclase is expressed to any
signiﬁcant extent in T cells, and whether impaired func-
tion of AE2 in T cells leads to chronically elevated
cAMP levels and consequent induction of ICER.
The functional nature of the human variant AE2 gene
highlighted by Poupon et al. [10] in the present issue
remains to be elucidated, but the potential for targeted
therapeutic interventions is intriguing [22].
Apart from these considerations on pathophysiologi-
cal aspects of PBC, we would like to add some general
remarks with regard to genetic association studies. These
are often plagued by lack of reproducibility caused by
false-negative and, more frequently, false-positive associ-
ations. False-positive associations can be caused by hid-
den stratiﬁcation within the case or control group, by
statistical ﬂuctuation, or by the inappropriate use of p-
values of 0.05 as a threshold criterion for success. New-
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studies should utilize prior probability estimates on basis
of the type of association that is studied. This involves
estimation of the number of candidate genes involved in
a certain disease, the odds ratio of an involved gene and
whether a gene represents a major or minor determinant.
They calculated that in the best case scenario (a top can-
didate gene in a polygenic diseasewith an odds ratio lower
than 1.5) one should use a p < 0.003 rather than 0.05. On
thebasis of this approach, they also calculated thatwhen a
p < 0.05 is used in such a studywith 200 cases and 200 con-
trols, the chance of ﬁnding a true-positive association is
1.7%. If a p < 0.001 is applied this chance increases to
26%. When the same study involves 2000 cases and 2000
controls, the chance of true positivity increases to 4.9%
(with p < 0.05%) and 60% (with p < 0.001). These calcula-
tions demonstrate that conclusions from small associa-
tion studies have to be interpreted cautiously.
In summary, the data provided by Poupon et al. [10]
are intriguing with regard to a potential role of ABCB1,
PXR and, in particular, AE2 gene variants in the devel-
opment and progression of PBC. However, conﬁrma-
tion of these data in large and independent cohorts of
PBC patients is warranted.
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